Application Lopinavir has been used as a ZMPSTE24 and human immunodeficiency virus protease inhibitor. Biochem/physiol Actions Lopinavir is an antiviral HIV Protease Inhibitor.
Application Lopinavir has been used as a ZMPSTE24 and human immunodeficiency virus protease inhibitor. Biochem/physiol Actions Lopinavir is an antiviral HIV Protease Inhibitor.
Application Lopinavir has been used as a ZMPSTE24 and human immunodeficiency virus protease inhibitor. Biochem/physiol Actions Lopinavir is an antiviral HIV Protease Inhibitor.
Application Lopinavir has been used as a ZMPSTE24 and human immunodeficiency virus protease inhibitor. Biochem/physiol Actions Lopinavir is an antiviral HIV Protease Inhibitor.
General description Chromatin assembly factor I (CAF1) is a nuclear complex consisting of p50, p60 (CHAF1B: MIM 601245), and p150 (CHAF1A) subunits that assembles histone octamers onto replicating DNA in vitro (Kaufman et al., 1995 [PubMed
General description Chromatin assembly factor I (CAF1) is a nuclear complex consisting of p50, p60 (CHAF1B: MIM 601245), and p150 (CHAF1A) subunits that assembles histone octamers onto replicating DNA in vitro (Kaufman et al., 1995 [PubMed
General description Lopinavir is an antiretroviral agent and a protease inhibitor indicated for the management of human immunodeficiency virus (HIV) infection. It is a key component of Kaletra, the co-formulation of lopinavir and ritonavir.
General description Lopinavir is an antiretroviral agent and a protease inhibitor indicated for the management of human immunodeficiency virus (HIV) infection. It is a key component of Kaletra, the co-formulation of lopinavir and ritonavir.
General description CRISPRi is a potent tool for modulating gene expression. This technology uses dCas9 to act as a synthetic transcription factors by recruiting endogenous transcription repressor complexes to gene promoters and enhancers,
General description CRISPRi is a potent tool for modulating gene expression. This technology uses dCas9 to act as a synthetic transcription factors by recruiting endogenous transcription repressor complexes to gene promoters and enhancers,
General description The small ubiquitin-related modifier SUMO-1 belongs to the growing family of ubiquitin-related proteins involved in post translational protein modification1. It is present in all eukaryotic kingdoms and is highly conserved from
General description The small ubiquitin-related modifier SUMO-1 belongs to the growing family of ubiquitin-related proteins involved in post translational protein modification1. It is present in all eukaryotic kingdoms and is highly conserved from
Lopinavir is an antiviral HIV Protease Inhibitor. Lopinavir has insufficient bioavailability alone, so it is used in therapy in combination with Ritonavir, a HIV protease inhibitor, which inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that
Lopinavir is an antiviral HIV Protease Inhibitor. Lopinavir has insufficient bioavailability alone, so it is used in therapy in combination with Ritonavir, a HIV protease inhibitor, which inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that
Lopinavir is an antiviral HIV Protease Inhibitor. Lopinavir has insufficient bioavailability alone, so it is used in therapy in combination with Ritonavir, a HIV protease inhibitor, which inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that
Lopinavir is an antiviral HIV Protease Inhibitor. Lopinavir has insufficient bioavailability alone, so it is used in therapy in combination with Ritonavir, a HIV protease inhibitor, which inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that
Lopinavir is an antiviral HIV Protease Inhibitor. Lopinavir has insufficient bioavailability alone, so it is used in therapy in combination with Ritonavir, a HIV protease inhibitor, which inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that
Lopinavir is an antiviral HIV Protease Inhibitor. Lopinavir has insufficient bioavailability alone, so it is used in therapy in combination with Ritonavir, a HIV protease inhibitor, which inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that
Lopinavir is an antiviral HIV Protease Inhibitor. Lopinavir has insufficient bioavailability alone, so it is used in therapy in combination with Ritonavir, a HIV protease inhibitor, which inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that
Lopinavir is an antiviral HIV Protease Inhibitor. Lopinavir has insufficient bioavailability alone, so it is used in therapy in combination with Ritonavir, a HIV protease inhibitor, which inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that
Lopinavir is an antiviral HIV Protease Inhibitor. Lopinavir has insufficient bioavailability alone, so it is used in therapy in combination with Ritonavir, a HIV protease inhibitor, which inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that
Lopinavir is an antiviral HIV Protease Inhibitor. Lopinavir has insufficient bioavailability alone, so it is used in therapy in combination with Ritonavir, a HIV protease inhibitor, which inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that
Lopinavir is an antiviral HIV Protease Inhibitor. Lopinavir has insufficient bioavailability alone, so it is used in therapy in combination with Ritonavir, a HIV protease inhibitor, which inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that
Lopinavir is an antiviral HIV Protease Inhibitor. Lopinavir has insufficient bioavailability alone, so it is used in therapy in combination with Ritonavir, a HIV protease inhibitor, which inhibits cytochrome P450-3A4 (CYP3A4), a liver enzyme that